Dexborneol Amplifies Pregabalin’s Analgesic Effect in Mouse Models of Peripheral Nerve Injury and Incisional Pain
Open Access
- 2 July 2024
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 13 (7) , 803
Abstract
Pregabalin is a medication primarily used in the treatment of neuropathic pain and anxiety disorders, owing to its gabapentinoid properties. Pregabalin monotherapy faces limitations due to its variable efficacy and dose-dependent adverse reactions. In this study, we conducted a comprehensive investigation into the potentiation of pregabalin’s analgesic effects by dexborneol, a neuroprotective bicyclic monoterpenoid compound. We performed animal experiments where pain models were induced using two methods: peripheral nerve injury, involving axotomy and ligation of the tibial and common peroneal nerves, and incisional pain through a longitudinal incision in the hind paw, while employing a multifaceted methodology that integrates behavioral pharmacology, molecular biology, neuromorphology, and lipidomics to delve into the mechanisms behind this potentiation. Dexborneol was found to enhance pregabalin’s efficacy by promoting its transportation to the central nervous system, disrupting self-amplifying vicious cycles via the reduction of HMGB1 and ATP release, and exerting significant anti-oxidative effects through modulation of central lipid metabolism. This combination therapy not only boosted pregabalin’s analgesic property but also notably decreased its side effects. Moreover, this therapeutic cocktail exceeded basic pain relief, effectively reducing neuroinflammation and glial cell activation—key factors contributing to persistent and chronic pain. This study paves the way for more tolerable and effective analgesic options, highlighting the potential of dexborneol as an adjuvant to pregabalin therapy.Keywords
Funding Information
- National Natural Science Foundation of China (82374061, 2022-I2M-1-016, ZZ-JQ2023008)
- CAMS Innovation Fund for Medical Sciences (82374061, 2022-I2M-1-016, ZZ-JQ2023008)
- the Fundamental Research Funds for the Central public welfare research institutes (82374061, 2022-I2M-1-016, ZZ-JQ2023008)
This publication has 64 references indexed in Scilit:
- Diosmin nanocrystal gel alleviates imiquimod-induced psoriasis in rats via modulating TLR7,8/NF-κB/micro RNA-31, AKT/mTOR/P70S6K milieu, and Tregs/Th17 balanceInflammopharmacology, 2023
- Interactions of glial cells with neuronal synapses, from astrocytes to microglia and oligodendrocyte lineage cellsGlia, 2023
- α‐Asarone attenuates chronic sciatica by inhibiting peripheral sensitization and promoting neural repairPhytotherapy Research, 2022
- Current Issues in the Use of Opioids for the Management of Postoperative PainJAMA Surgery, 2022
- “Lipidomics”: Mass spectrometric and chemometric analyses of lipidsAdvanced Drug Delivery Reviews, 2020
- Presynaptic NMDA receptors control nociceptive transmission at the spinal cord level in neuropathic painCellular and Molecular Life Sciences, 2019
- Pregabalin for neuropathic pain in adultsCochrane Database of Systematic Reviews, 2019
- Neuroinflammation in the central nervous system: Symphony of glial cellsGlia, 2018
- Gabapentin for chronic neuropathic pain in adultsCochrane Database of Systematic Reviews, 2017
- Analgesic effect of sinomenine in rodents after inflammation and nerve injuryEuropean Journal of Pharmacology, 2013